Overcoming the COV-BARRIER: The Role of Baricitinib in SARS-CoV-2

<p>Aeryana N. Beaudrie-Nunn, Pharm.D. (<a href='https://twitter.com/ABeaudrieRx'>@ABeaudrieRx</a>), identifies the rationale for immunodulatory therapy in COVID-19, explores clinical trial data regarding the use of Baricitinib in hospitalized patients with COVID-19, and defines the patient context where Baricitinib use is most appropriate. </p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>